Shanghai OPM Biosciences Co., Ltd. (SHA:688293)
China · Delayed Price · Currency is CNY 55.88
+2.32 (4.33%)
At close: Sep 2, 2026
Shanghai OPM Biosciences Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,459 | 5,577 | 4,148 | 6,332 | 8,460 | - | |
Market Cap Growth | 22.33% | 34.44% | -34.49% | -25.16% | - | - |
Enterprise Value | 5,808 | 4,263 | 2,834 | 4,889 | 6,795 | - |
Last Close Price | 53.56 | 48.77 | 35.98 | 53.64 | 70.83 | - |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 181.55 | 133.75 | 197.05 | 117.18 | 80.29 | - |
Forward PE | 82.40 | 55.21 | 40.23 | 64.15 | - | - |
PS Ratio | 16.45 | 15.71 | 13.96 | 26.04 | 28.74 | - |
PB Ratio | 2.72 | 2.66 | 1.98 | 2.93 | 3.87 | - |
P/TBV Ratio | 3.59 | 2.70 | 2.02 | 2.99 | 3.95 | - |
P/FCF Ratio | - | 117.85 | - | - | - | - |
P/OCF Ratio | 134.61 | 53.94 | 59.91 | 109.26 | 75.80 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 12.81 | 12.01 | 9.53 | 20.11 | 23.08 | - |
EV/EBITDA Ratio | 87.73 | 67.93 | 66.58 | 103.93 | 59.98 | - |
EV/EBIT Ratio | - | 189.88 | 438.58 | 256.99 | 76.35 | - |
EV/FCF Ratio | - | 90.07 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.06 | 0.03 | 0.03 | 0.03 | 0.04 | 0.22 |
Debt / EBITDA Ratio | 2.56 | 0.79 | 1.25 | 1.24 | 0.75 | 1.45 |
Debt / FCF Ratio | - | 1.20 | - | - | - | 14.09 |
Net Debt / Equity Ratio | -0.60 | -0.61 | -0.61 | -0.65 | -0.74 | -0.41 |
Net Debt / EBITDA Ratio | -29.27 | -20.55 | -29.84 | -30.06 | -14.34 | -3.08 |
Net Debt / FCF Ratio | 844.86 | -27.25 | 24.61 | 72.18 | 45.98 | -26.48 |
Asset Turnover | 0.14 | 0.16 | 0.13 | 0.11 | 0.19 | 0.33 |
Inventory Turnover | 2.06 | 2.74 | 2.63 | 2.18 | 2.76 | 3.72 |
Quick Ratio | 1.71 | 18.90 | 12.18 | 22.37 | 20.18 | 4.09 |
Current Ratio | 1.90 | 20.36 | 12.97 | 23.49 | 20.94 | 4.60 |
Return on Equity (ROE) | 2.64% | 1.96% | 0.95% | 2.45% | 7.67% | 11.43% |
Return on Assets (ROA) | 0.29% | 0.62% | 0.18% | 0.51% | 3.60% | 5.35% |
Return on Invested Capital (ROIC) | 1.52% | 2.28% | 0.46% | 2.52% | 17.58% | 17.84% |
Return on Capital Employed (ROCE) | 0.50% | 1.00% | 0.30% | 0.90% | 3.90% | 8.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 0.89% | 0.75% | 0.51% | 0.85% | 1.24% | - |
FCF Yield | -0.03% | 0.85% | -1.24% | -0.31% | -0.42% | - |
Dividend Yield | 0.67% | 0.88% | 1.17% | 0.82% | 0.60% | - |
Payout Ratio | 73.69% | 117.09% | 243.29% | 136.63% | 1.97% | 2.99% |
Buyback Yield / Dilution | -93.00% | 3.64% | -1.72% | -13.48% | -17.43% | -0.20% |
Total Shareholder Return | -92.33% | 4.52% | -0.56% | -12.66% | -16.83% | -0.20% |